Literature DB >> 21621081

Doppler blood flow analysis of erectile function: who, when, and how.

Timothy J LeRoy1, Gregory A Broderick.   

Abstract

The underlying processes in vasculogenic erectile dysfunction (ED) are arterial insufficiency, venoocclusive disease, or combinations of both. Doppler blood flow analysis is a diagnostic modality useful in elucidating the cause of ED and the magnitude of its severity. This article describes the procedural techniques, typical findings, and relevant pathophysiology for in-office Doppler studies. Specific conditions include arterial insufficiency, venous occlusive disease, Peyronie's disease, and priapism. 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21621081     DOI: 10.1016/j.ucl.2011.03.003

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  5 in total

1.  How I treat priapism.

Authors:  Uzoma A Anele; Brian V Le; Linda M S Resar; Arthur L Burnett
Journal:  Blood       Date:  2015-03-25       Impact factor: 22.113

Review 2.  Prophylactic phenylephrine for iatrogenic priapism: a pilot study with Peyronie's patients.

Authors:  Pengbo Jiang; Athena Christakos; Mina Fam; Hossein Sadeghi-Nejad
Journal:  Korean J Urol       Date:  2014-10-10

Review 3.  Priapism: current updates in clinical management.

Authors:  Phil Hyun Song; Ki Hak Moon
Journal:  Korean J Urol       Date:  2013-12-10

4.  Resolution of erectile dysfunction after an andrological visit in a selected population of patients affected by psychogenic erectile dysfunction.

Authors:  Giorgio Cavallini
Journal:  Asian J Androl       Date:  2017 Mar-Apr       Impact factor: 3.285

5.  Variability in penile duplex ultrasound international practice patterns, technique, and interpretation: an anonymous survey of ISSM members.

Authors:  Mohit Butaney; Nannan Thirumavalavan; Mark S Hockenberry; E Will Kirby; Alexander W Pastuszak; Larry I Lipshultz
Journal:  Int J Impot Res       Date:  2018-08-14       Impact factor: 2.896

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.